GlycoMimetics (GLYC) Given Media Sentiment Score of 0.15
News stories about GlycoMimetics (NASDAQ:GLYC) have trended somewhat positive recently, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. GlycoMimetics earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 47.8366771153335 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- GlycoMimetics to Present at Upcoming Healthcare Investor Conferences – Business Wire (press release) (businesswire.com)
- GlycoMimetics, Inc. (GLYC) to Post Q1 2018 Earnings of ($0.25) Per Share, Jefferies Group Forecasts (americanbankingnews.com)
- GlycoMimetics, Inc. (GLYC) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS (americanbankingnews.com)
- GlycoMimetics Reports Program Updates and Third Quarter 2017 Results – Business Wire (press release) (businesswire.com)
- Edited Transcript of GLYC earnings conference call or presentation 8-Nov-17 1:30pm GMT (finance.yahoo.com)
GlycoMimetics (GLYC) traded up $0.38 during trading on Friday, reaching $11.71. 370,100 shares of the company were exchanged, compared to its average volume of 574,856. GlycoMimetics has a 1 year low of $3.82 and a 1 year high of $16.94.
GlycoMimetics (NASDAQ:GLYC) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. analysts forecast that GlycoMimetics will post -1.15 earnings per share for the current fiscal year.
A number of research analysts recently commented on GLYC shares. Zacks Investment Research upgraded shares of GlycoMimetics from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Tuesday, July 18th. Stifel Nicolaus reiterated a “buy” rating and set a $17.00 price objective (up previously from $13.00) on shares of GlycoMimetics in a research note on Friday, August 4th. SunTrust Banks, Inc. set a $21.00 price objective on shares of GlycoMimetics and gave the company a “buy” rating in a research note on Monday, August 7th. BidaskClub upgraded shares of GlycoMimetics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. Finally, ValuEngine upgraded shares of GlycoMimetics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $17.67.
ILLEGAL ACTIVITY NOTICE: “GlycoMimetics (GLYC) Given Media Sentiment Score of 0.15” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/glycomimetics-glyc-given-media-sentiment-score-of-0-15/1698281.html.
In related news, SVP Helen M. Thackray sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $13.00, for a total value of $26,000.00. Following the completion of the transaction, the senior vice president now owns 150,615 shares of the company’s stock, valued at approximately $1,957,995. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 43.80% of the company’s stock.
GlycoMimetics Company Profile
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
Receive News & Ratings for GlycoMimetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.